CytoSorbents Corporation announced that it has entered into a multi-country strategic partnership with Fresenius Medical Care AG & CO KGaA to commercialize CytoSorbents’ CytoSorb® therapy in the Nordic countries.
Under the terms of the agreement, Fresenius Medical Care will have the exclusive rights to distribute CytoSorb® for critical care applications in France, Poland, Sweden, Denmark, Norway and Finland. The partnership will allow Fresenius Medical Care to offer blood purification therapy for removing cytokines in patients who are treated in intensive care units.
To promote CytoSorb®, Fresenius will also engage in the ongoing clinical development of the product. This includes the support and publication of a number of small case series and patient case reports as well as the potential for future larger, clinical collaborations. This multi-year agreement is subject to annual minimum guaranteed orders of CytoSorb® to maintain exclusivity.
CytoSorb® is approved in the European Union as a safe and effective extracorporeal cytokine absorber to reduce the excessive production of inflammatory mediators called cytokines, or “cytokine storm”, in life-threatening illnesses. Left unchecked, cytokine storm can lead to whole-body inflammation, resulting in organ failure, the leading cause of death in intensive care units.